

Optimal Minimal Stent Area and Impact of Stent Underexpansion in Left Main Up-Front 2-Stent Strategy


Ju Hyeon Kim^{ID}, MD; Do-Yoon Kang^{ID}, MD, PhD; Jung-Min Ahn^{ID}, MD, PhD; Jihoon Kweon^{ID}, PhD; Yeonwoo Choi^{ID}, MD; Hoyun Kim, MD; Jinho Lee^{ID}, MD; Jihye Chae, BS; Soo-Jin Kang^{ID}, MD, PhD; Duk-Woo Park^{ID}, MD, PhD; Seung-Jung Park^{ID}, MD, PhD

Background

- Current guidelines recommend the use of intracoronary imaging during **left-main (LM) stenting** because intravascular ultrasound (IVUS) guidance can improve clinical outcomes by ensuring well-apposed and adequately expanded stents.
- Previously proposed criteria for **optimal stent expansion** were based on IVUS-measured **minimal stent area (MSA)** in patients undergoing LM stenting to predict angiographic restenosis.

Kang SJ, et al. *Circ Cardiovasc Interv.* 2011;4:562-569

“5-6-7-8” MSA criteria



- Between March 2003 and May 2009
- Heterogeneous population (n=403)
a single-stent (n=289, 72%)
an upfront two-stent (28%)
- Predicted the risk of angiographic restenosis at 9-month follow-up


Objective

- To revise the MSA criteria for optimal stent expansion in patients undergoing an up-front 2-stent strategy using the crush technique for LM bifurcation lesions to predict the 5-year clinical outcomes.

Methods



- We identified 292 consecutive patients with LM bifurcation stenosis who were treated using the crush technique from March 2005 to December 2019.
- MSA within the ostial LAD, ostial LCX, and distal LM
- 5-year MACE, including all-cause death, myocardial infarction, and target lesion revascularization related to LM stenosis.

IVUS-measured Minimal Stent Area




- N = 292
- 64.0 ± 9.9 years
- Male, 224 (76.7%)
- Diabetes, 98 (33.6%)
- 1st DES, 52 (17.8%)

Distal LM



A


Major Adverse Cardiac Events

**No. at risk**

| | | | | | | |
|---------------------------------|-----|-----|-----|-----|-----|-----|
| — LM MSA < 11.8 mm ² | 189 | 178 | 173 | 155 | 141 | 125 |
| — LM MSA ≥ 11.8 mm ² | 103 | 102 | 94 | 87 | 67 | 56 |

LAD AUROC = 0.62

B




No. at risk

| | | | | | | |
|---------------------------------|-----|-----|-----|-----|-----|----|
| — LAD MSA < 8.3 mm ² | 161 | 152 | 142 | 128 | 114 | 98 |
| — LAD MSA ≥ 8.3 mm ² | 131 | 128 | 125 | 114 | 94 | 83 |

LCX AUROC = 0.64


C




No. at risk


| | | | | | | |
|---------------------------------|-----|-----|-----|-----|-----|----|
| — LCX MSA < 5.7 mm ² | 141 | 132 | 124 | 114 | 103 | 93 |
| — LCX MSA ≥ 5.7 mm ² | 151 | 148 | 143 | 128 | 105 | 88 |

Stent Under-Expansion Criteria in LM Two-Stenting With the Crush Technique




The Optimal Minimal Stent Area within Each Left Main Segment





“5 – 6 – 7 – 8” Criteria



No. at risk

| | | | | | | |
|-----------------------|-----|-----|-----|-----|-----|-----|
| — Under-expansion (+) | 83 | 77 | 74 | 69 | 66 | 59 |
| — Under-expansion (-) | 209 | 203 | 193 | 173 | 142 | 122 |

Major Adverse Cardiac Events at 5 Years according to Stent Under-Expansion

5-Year Rate of Major Adverse Cardiac Events (%)

Under-Expansion

LAD MSA < 8.3 mm² and
LCX MSA < 5.7 mm²

23.1 %

Full-Expansion

LAD MSA ≥ 8.3 mm² and
LCX MSA ≥ 5.7 mm²

6.4 %

Adjusted HR, 5.49
(95% CI, 2.10–14.3), p<0.001

(%)

10


20

30



Patients who underwent two-stent PCI with the crush technique and had complete post-stenting IVUS images from both LAD and LCX pullback (N=292)

Grouped by IVUS-measured final MSA



Group 0
LAD MSA $\geq 8.3 \text{ mm}^2$ and
LCX MSA $\geq 5.7 \text{ mm}^2$
(N=94)

Group 1


- LAD MSA $\geq 8.3 \text{ mm}^2$ and
LCX MSA $< 5.7 \text{ mm}^2$
- LAD MSA $< 8.3 \text{ mm}^2$ and
LCX MSA $\geq 5.7 \text{ mm}^2$

(N=94)





Group 2
LAD MSA $< 8.3 \text{ mm}^2$ and
LCX MSA $< 5.7 \text{ mm}^2$
(N=104)

A


Major Adverse Cardiac Events

**No. at risk**

| | | | | | | |
|-----------|-----|----|----|----|----|----|
| — Group 2 | 104 | 96 | 88 | 79 | 73 | 64 |
| — Group 1 | 94 | 92 | 90 | 84 | 71 | 63 |
| — Group 0 | 94 | 92 | 89 | 79 | 64 | 54 |

A**“5-6-7-8” Criteria****EXCEL Criteria****Relative MSA Criteria****B****“6-8-10” Criteria (Minimal)
“7-9-12” Criteria (Optimal)**


Smaller caliber arteries
→

Relative MSA Criteria**Figure. Expansion criteria.**

A, Existing stent expansion criteria for distal left main (LM) bifurcation stenting.

B, Proposed stent expansion criteria for LM stenting. LAD indicates left anterior descending; LCX, left circumflex; and MSA, minimal stent area.

Major Adverse Cardiac Events



No. at risk

| | | | | | | |
|------------------------|-----|-----|-----|-----|-----|-----|
| — Newer-generation DES | 240 | 231 | 220 | 196 | 163 | 137 |
| — First-generation DES | 52 | 49 | 47 | 46 | 45 | 44 |

| | Total | Single Stent | Two-Stent | <i>P</i> Value |
|--------------------------------------|----------|--------------|-----------|----------------|
| LAD ostium, n† | 336 | 222 | 114 | |
| MSA, mm ² | 8.1±1.8 | 8.3±1.8 | 7.8±1.7 | 0.015 |
| EEM area at the MSA, mm ² | 16.6±3.7 | 16.8±3.8 | 16.3±3.4 | 0.172 |
| Peristent plaque burden, % | 50.6±8.0 | 50.0±8.2 | 51.7±7.4 | 0.067 |
| MSA <6.3 mm ² | 58 (17%) | 29 (13%) | 29 (25%) | 0.004 |
| POC, n† | 336 | 222 | 114 | |
| MSA, mm ² | 8.7±1.9 | 9.1±1.9 | 8.1±1.8 | <0.001 |
| MSA <7.2 mm ² | 77 (23%) | 40 (18%) | 37 (33%) | 0.003 |
| Proximal LM above the POC, n | 403 | 289 | 114 | |
| MSA, mm ² | 10.2±2.4 | 10.0±2.2 | 10.5±2.8 | 0.055 |
| EEM area at the MSA, mm ² | 21.8±5.1 | 21.8±5.2 | 21.8±4.7 | 0.936 |
| Peristent plaque burden, % | 52.2±9.2 | 53.0±9.0 | 50.2±9.3 | 0.007 |
| MSA <8.2 mm ² | 83 (21%) | 60 (21%) | 23 (20%) | 0.896 |
| LCX ostium, by LCX pullback,* n | | | 104 | |
| MSA, mm ² | | | 5.6±1.4 | |
| EEM area at the MSA, mm ² | | | 11.8±2.8 | |
| Peristent plaque burden, % | | | 51.7±9.3 | |
| MSA <5.0 mm ² | | | 38 (37%) | |

| Characteristics | Overall population (N=292) | MACEs | | P value |
|---|----------------------------|-------------|------------|---------|
| | | No (n=257) | Yes (n=35) | |
| Distal LM | | | | |
| MSA, mm ² | 10.9±2.2 | 11.0±2.2 | 10.4±2.0 | 0.135 |
| EEM area at the MSA site, mm ² | 23.8±4.1 | 23.9±4.2 | 22.9±4.1 | 0.180 |
| MSA <11.8 mm ² | 189 (64.7%) | 163 (63.4%) | 26 (74.3%) | 0.283 |
| Stent expansion index | 46.4±7.2 | 46.4±7.3 | 46.0±7.0 | 0.730 |
| LAD ostium | | | | |
| MSA, mm ² | 8.2±1.7 | 8.2±1.7 | 7.6±1.2 | 0.004 |
| EEM area at the MSA site, mm ² | 17.3±3.4 | 17.4±3.4 | 16.5±3.2 | 0.114 |
| MSA <8.3 mm ² | 161 (55.1%) | 133 (51.8%) | 28 (80.0%) | 0.003 |
| Stent expansion index | 47.7±7.6 | 47.8±7.9 | 46.7±5.7 | 0.274 |
| LCX ostium, by LCX pullback | | | | |
| MSA, mm ² | 5.9±1.4 | 6.0±1.5 | 5.3±1.1 | 0.007 |
| EEM area at the MSA site, mm ² | 13.2±3.2 | 13.3±3.0 | 12.8±4.0 | 0.529 |
| MSA <5.7 mm ² | 141 (48.3%) | 116 (45.1%) | 25 (71.4%) | 0.006 |
| Stent expansion index | 45.7±8.6 | 46.0±8.5 | 43.4±8.6 | 0.082 |

Summary

- Stent **under-expansion** was significantly associated with long-term **clinical outcomes** in patients who underwent two-stenting for LM bifurcation stenosis.
- This study advocated the **imaging-guided** stent **optimization** to achieve **maximal MSA** for better clinical outcome.